原鈣粘蛋白15在NK/T細胞淋巴瘤診斷中的價值_《華西醫學》

作者：

四川大學華西醫院血液科、血液病研究室（成都，610041）;

關鍵詞：

鈣粘蛋白原鈣粘蛋白15 NK/T細胞淋巴瘤免疫表型診斷

DOI：

10.7507/1002-0179.20130247

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

原鈣粘蛋白15（PCDH15），作為鈣粘蛋白超家族的成員，在人類由位于10號染色體q21的PCDH15基因編碼，它包括11個重復胞外鈣結合結構域、一個跨膜區和一個獨特的胞質域，分為四個亞型：PCDH15-CD1、CD2、CD3和不含跨膜區與胞漿區的PCDH15-SI亞型。在YT型NK/T淋巴瘤細胞株研究中發現的PCDH15-SI亞型，其結構和功能與以往所知的PCDH15有很大差異，在正常T、B及NK淋巴細胞及其活化后均不表達，而在NK/T細胞淋巴瘤特異表達。這一發現有可能讓PCDH15-SI型成為NK/T細胞淋巴瘤診斷中的有價值的新的生物標記。

引用本文： 周佳麗,徐才剛. 原鈣粘蛋白15在NK/T細胞淋巴瘤診斷中的價值. 華西醫學, 2013, 28(5): 799-801. doi: 10.7507/1002-0179.20130247 復制

1.	Angst BD, Cristiana M. The cadherin superfamily: diversity in form and Function[J]. Cell Sci, 2001,114 (Pt 4): 629-641.
2.	Paco Hulpiaua, Frans van Roy. Molecular evolution of the cadherin superfamily[J]. Int J Biochem Cell Biol, 2009, 41(2): 349-369.
3.	田立立, 王艷麗, 黃韌. 腫瘤轉移中E-鈣粘蛋白的調控[J]. 中國實驗動物學報, 2012, 20(3): 81-85.
4.	朱煊, 彭再如, 劉洋, 等. 前列腺癌組織中E2鈣粘蛋白和環氧化酶2表達的研究[J]. 現代泌尿生殖腫瘤雜志, 2009, 1(2): 98-101.
5.	蔣小雷, 盧東, 吳明輝, 等. 膀胱移行細胞癌中S100A4蛋白和鈣粘蛋白-E表達及意義[J]. 西部醫學, 2012, 24(10): 1863-1866.
6.	Suo L, Lu H, Ying G, et al. Protocadherin clusters and cell adhesion kinase regulate dendrite complexity through Rho GTPase[J]. J Mol Cell Biol, 2012, 4(6): 362-376.
7.	Frank M, Kemler R. Protocadherins[J]. Curr Opin Cell Biol, 2002, 14(5): 557-562.
8.	于鈺, 索倫, 吳強. PCDHα在髓鞘形成和少突膠質細胞發育中的作用[J].動物學研究, 2012, 33(4): 362-366.
9.	Hirano K, Kaneko R, Izawa T, et al. Single-neuron diversity generated by Protocadheri-βcluster in mouse central and periphera lnervous systems[J]. Front Mol Neurosci, 2012, 5(90):1-13.
10.	Lin YL, Li ZG, Guan TY. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma[J]. Urol Int, 2013, 90(2): 219-24.
11.	Ahmed ZM, Riazuddin S, Aye S, et al. Gene structure and mutant alleles of PCDH15: nonsyndromic deafness DFNB23 and type 1 Usher syndrome[J]. Hum Genet, 2008, 124(3): 215-223.
12.	Ahmed ZM, Riazuddin S, Ahmad J, et al. PCDH15 is expressed in the neurosensory epithelium of the eye and ear and mutant alleles are responsible for both USH1F and DFNB23[J]. Hum Mol Genet, 2003, 12(24): 3215-3223.
13.	Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, et al. Protocadherin 15 (PCDH15):a new secreted isoformand a potential marker for NK/T cell lymphomas[J]. Oncogene, 2006, 25(19): 2807-2811.
14.	Mansur IG, Leca G, Pratt JC, et al. Identification of a novel functional 85-kD glycoprotein restricted to long-term dividing human lymphocytic lines[J]. Hum Immunol, 1993, 37(1): 31-38.
15.	Lanier LL.Nk cell recognition[J]. Annu Rev Immunol, 2005, 23: 225-274.
16.	Ham MF, Ko YH. Natural killer cell neoplasm: biology and pathology[J]. Int J Hematol, 2010, 92(5): 681-689.
17.	Seishima M, Yuge M, Kosugi H, et al. Extranodal NK/T-cell Lymphoma, Nasal Type, Possibly Arising from Chronic Epstein-Barr Virus Infection[J]. Acta Derm Venereol, 2010, 90(1): 102-103.
18.	Choi YL, Park JH, Namkung JH, et al. Extranodal NK/T-cell lymphoma with cutaneous involvement: ‘nasal’ vs. ‘nasal-type’ subgroups-a retrospective study of 18 patients[J]. Br J Dermatol, 2009, 160(2): 333-337.
19.	Kim TM, Lee SY, Leon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma,nasal type: a national survey of the Korean Cancer Study Group[J]. Ann Oncol, 2008, 19(8): 1477-1484.
20.	Pongpruttipan T, Kummalue T, Bedavanija A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand[J]. Diagn Pathol, 2011, 6: 79.
21.	Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients[J]. Blood, 2004, 104(1): 243-249.
22.	Jaccard A, Nathalie Gachard, Benoit Marin, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone(AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study[J]. Blood, 2012, 117(6): 1834-1839.
23.	Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Oncol, 2011, 22(1): 149-155.

1. 　Angst BD, Cristiana M. The cadherin superfamily: diversity in form and Function[J]. Cell Sci, 2001,114 (Pt 4): 629-641.
2. 　Paco Hulpiaua, Frans van Roy. Molecular evolution of the cadherin superfamily[J]. Int J Biochem Cell Biol, 2009, 41(2): 349-369.
3. 　田立立, 王艷麗, 黃韌. 腫瘤轉移中E-鈣粘蛋白的調控[J]. 中國實驗動物學報, 2012, 20(3): 81-85.
4. 　朱煊, 彭再如, 劉洋, 等. 前列腺癌組織中E2鈣粘蛋白和環氧化酶2表達的研究[J]. 現代泌尿生殖腫瘤雜志, 2009, 1(2): 98-101.
5. 　蔣小雷, 盧東, 吳明輝, 等. 膀胱移行細胞癌中S100A4蛋白和鈣粘蛋白-E表達及意義[J]. 西部醫學, 2012, 24(10): 1863-1866.
6. 　Suo L, Lu H, Ying G, et al. Protocadherin clusters and cell adhesion kinase regulate dendrite complexity through Rho GTPase[J]. J Mol Cell Biol, 2012, 4(6): 362-376.
7. 　Frank M, Kemler R. Protocadherins[J]. Curr Opin Cell Biol, 2002, 14(5): 557-562.
8. 　于鈺, 索倫, 吳強. PCDHα在髓鞘形成和少突膠質細胞發育中的作用[J].動物學研究, 2012, 33(4): 362-366.
9. 　Hirano K, Kaneko R, Izawa T, et al. Single-neuron diversity generated by Protocadheri-βcluster in mouse central and periphera lnervous systems[J]. Front Mol Neurosci, 2012, 5(90):1-13.
10. 　Lin YL, Li ZG, Guan TY. The clinical significance of PCDH10 promoter methylation in patients with bladder transitional cell carcinoma[J]. Urol Int, 2013, 90(2): 219-24.
11. 　Ahmed ZM, Riazuddin S, Aye S, et al. Gene structure and mutant alleles of PCDH15: nonsyndromic deafness DFNB23 and type 1 Usher syndrome[J]. Hum Genet, 2008, 124(3): 215-223.
12. 　Ahmed ZM, Riazuddin S, Ahmad J, et al. PCDH15 is expressed in the neurosensory epithelium of the eye and ear and mutant alleles are responsible for both USH1F and DFNB23[J]. Hum Mol Genet, 2003, 12(24): 3215-3223.
13. 　Rouget-Quermalet V, Giustiniani J, Marie-Cardine A, et al. Protocadherin 15 (PCDH15):a new secreted isoformand a potential marker for NK/T cell lymphomas[J]. Oncogene, 2006, 25(19): 2807-2811.
14. 　Mansur IG, Leca G, Pratt JC, et al. Identification of a novel functional 85-kD glycoprotein restricted to long-term dividing human lymphocytic lines[J]. Hum Immunol, 1993, 37(1): 31-38.
15. 　Lanier LL.Nk cell recognition[J]. Annu Rev Immunol, 2005, 23: 225-274.
16. 　Ham MF, Ko YH. Natural killer cell neoplasm: biology and pathology[J]. Int J Hematol, 2010, 92(5): 681-689.
17. 　Seishima M, Yuge M, Kosugi H, et al. Extranodal NK/T-cell Lymphoma, Nasal Type, Possibly Arising from Chronic Epstein-Barr Virus Infection[J]. Acta Derm Venereol, 2010, 90(1): 102-103.
18. 　Choi YL, Park JH, Namkung JH, et al. Extranodal NK/T-cell lymphoma with cutaneous involvement: ‘nasal’ vs. ‘nasal-type’ subgroups-a retrospective study of 18 patients[J]. Br J Dermatol, 2009, 160(2): 333-337.
19. 　Kim TM, Lee SY, Leon YK, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma,nasal type: a national survey of the Korean Cancer Study Group[J]. Ann Oncol, 2008, 19(8): 1477-1484.
20. 　Pongpruttipan T, Kummalue T, Bedavanija A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand[J]. Diagn Pathol, 2011, 6: 79.
21. 　Au WY, Pang A, Choy C, et al. Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients[J]. Blood, 2004, 104(1): 243-249.
22. 　Jaccard A, Nathalie Gachard, Benoit Marin, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone(AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study[J]. Blood, 2012, 117(6): 1834-1839.
23. 　Huang JJ, Jiang WQ, Lin TY, et al. Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Oncol, 2011, 22(1): 149-155.

上一篇
艾拉莫德在類風濕關節炎治療中的研究
下一篇
五氟利多所致藥源性帕金森綜合征一例

《華西醫學》

原鈣粘蛋白15在NK/T細胞淋巴瘤診斷中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

原鈣粘蛋白15在NK/T細胞淋巴瘤診斷中的價值

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料